Patents by Inventor Jérémy Besnard

Jérémy Besnard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051327
    Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of MALT-1. Such compounds are represented by Formula (I) and Formula (II), wherein the variables are defined herein.
    Type: Application
    Filed: November 23, 2021
    Publication date: February 13, 2025
    Inventors: Peter Ray, David Evans, Anthony Bradley, Chris Radoux, Simon Richards, Catarina Santos, Jérémy Besnard, Andrew John Cooke, Sylvie Félicité Gomez, Lorène Nathalie Sabine Cazaux-Lerou, Marta Pinto, Sabrina Pucci, Claire Christiane Ginette Blanger
  • Publication number: 20240400556
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 5, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20240132489
    Abstract: An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory activity, and good selectivity.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 25, 2024
    Inventors: Xiaohui GU, Haiyun BAI, Olivier Rémy BARBEAU, Jérémy BESNARD
  • Publication number: 20240124504
    Abstract: An aromatic heterocyclic compound, and a pharmaceutical composition and an application thereof. Specifically disclosed are a compound as represented by formula I-A, a stereoisomer thereof, a diastereoisomer thereof, or a pharmaceutically acceptable salt of any one of the described substances, or a crystalline form or a solvate of any one of the described substances. The aromatic heterocyclic compound is novel in structure, and has good CDK7 inhibitory activity and good selectivity.
    Type: Application
    Filed: August 27, 2021
    Publication date: April 18, 2024
    Inventors: Xiaohui GU, Haiyun BAI, Olivier Rémy BARBEAU, Jérémy BESNARD
  • Publication number: 20230382911
    Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: July 28, 2023
    Publication date: November 30, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon BELL, Jérémy BESNARD, Anthony Richard BRADLEY, Luke GREEN, Wolfgang HAAP, Buelent KOCER, Andreas KUGLSTATTER, Xavier LUCAS, Patrizio MATTEI, Dmitry MAZUNIN, Claus RIEMER, Willem Paul VAN HOORN
  • Publication number: 20230227449
    Abstract: The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Hasane Ratni, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20230219953
    Abstract: The present invention provides compounds of formula I wherein X1, X2, X3, X4, R1, R1a, R1b, R2?, R2?, R3?, R3?, R6 and R7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
    Type: Application
    Filed: December 19, 2022
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Claus Riemer, Willem Paul Van Hoorn
  • Publication number: 20200013486
    Abstract: A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1-In) from the population (PG=0); and evaluating members (I1-In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n.
    Type: Application
    Filed: August 12, 2019
    Publication date: January 9, 2020
    Inventors: Andrew Lee Hopkins, Jérémy Besnard
  • Patent number: 10381110
    Abstract: A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1-In) from the population (PG=0); and evaluating members (I1-In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF DUNDEE
    Inventors: Andrew Lee Hopkins, Jérémy Besnard
  • Publication number: 20160196412
    Abstract: A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1-In) from the population (PG=0); and evaluating members (I1-In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 7, 2016
    Inventors: Andrew Lee Hopkins, Jérémy Besnard
  • Publication number: 20120265514
    Abstract: A method for computational drug design using an evolutionary algorithm, comprises evaluating virtual molecules according to vector distance (VD) to at least one achievement objective that defines a desired ideal molecule. In one method the invention comprises defining a set of n achievement objectives (OA1-n), where n is at least one; defining a population (PG=0) of at least one molecule; selecting an initial population (Pparent) of at least one molecule (I1?In) from the population (PG=0); and evaluating members (I1?In) of the initial population (Pparent) against at least one of the n achievement objectives (OA1-x), where x is from 1 to n.
    Type: Application
    Filed: November 22, 2010
    Publication date: October 18, 2012
    Inventors: Andrew Lee Hopkins, Jérémy Besnard